Cwm LLC Decreases Position in Bruker Corporation $BRKR

Cwm LLC lowered its position in Bruker Corporation (NASDAQ:BRKR) by 98.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,089 shares of the medical research company’s stock after selling 55,842 shares during the quarter. Cwm LLC’s holdings in Bruker were worth $35,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its stake in Bruker by 377.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank grew its position in shares of Bruker by 750.0% in the second quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 645 shares during the last quarter. Spire Wealth Management acquired a new stake in shares of Bruker in the second quarter valued at approximately $32,000. Parallel Advisors LLC increased its stake in shares of Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after purchasing an additional 347 shares in the last quarter. Finally, True Wealth Design LLC raised its position in shares of Bruker by 16,716.7% during the 2nd quarter. True Wealth Design LLC now owns 1,009 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,003 shares during the last quarter. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Bruker Stock Performance

NASDAQ:BRKR opened at $51.95 on Thursday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $61.01. The firm’s 50 day moving average is $47.70 and its two-hundred day moving average is $40.20. The company has a market cap of $7.89 billion, a P/E ratio of -324.69, a P/E/G ratio of 6.55 and a beta of 1.17. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last issued its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business’s quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the company posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BRKR shares. Guggenheim increased their target price on Bruker from $45.00 to $53.00 and gave the company a “buy” rating in a report on Monday, January 5th. Wells Fargo & Company increased their price objective on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Rothschild Redb upgraded Bruker to a “strong-buy” rating in a research report on Thursday, November 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Finally, Bank of America raised their price target on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Bruker currently has a consensus rating of “Moderate Buy” and an average price target of $53.36.

Insider Transactions at Bruker

In other news, Director John A. Ornell sold 6,233 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total transaction of $243,087.00. Following the transaction, the director directly owned 35,212 shares of the company’s stock, valued at approximately $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This trade represents a 5.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 15,233 shares of company stock worth $726,487. 27.30% of the stock is currently owned by insiders.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.